Tags

Type your tag names separated by a space and hit enter

A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria.
Bull World Health Organ. 1983; 61(4):713-8.BW

Abstract

A total of 99 male Zambian patients with symptomatic falciparum malaria were treated in a double-blind randomized manner with either mefloquine (1000 mg given in one day) or chloroquine (1500 mg given over 3 days). An S-type response was seen in all the chloroquine patients and 98% of the mefloquine group; one patient in the latter group (2%) showed an RI-type response, but the parasites obtained during the recrudescence were sensitive to both chloroquine and mefloquine in the in vitro microtest, and the patient responded satisfactorily to oral chloroquine. The rate of clearance of parasitaemia was marginally faster in the chloroquine-treated group. The rate of clearance of fever was similar in the two groups. Both drugs were well tolerated and side-effects such as nausea, vomiting, dizziness, loose stools, and pruritus were mild and transient. Pruritus was more common after chloroquine administration and dizziness more common in the mefloquine group. There were no drug-induced alterations in the haematological and biochemical profiles.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6354507

Citation

Kofi Ekue, J M., et al. "A Double-blind Comparative Clinical Trial of Mefloquine and Chloroquine in Symptomatic Falciparum Malaria." Bulletin of the World Health Organization, vol. 61, no. 4, 1983, pp. 713-8.
Kofi Ekue JM, Ulrich AM, Rwabwogo-Atenyi J, et al. A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull World Health Organ. 1983;61(4):713-8.
Kofi Ekue, J. M., Ulrich, A. M., Rwabwogo-Atenyi, J., & Sheth, U. K. (1983). A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bulletin of the World Health Organization, 61(4), 713-8.
Kofi Ekue JM, et al. A Double-blind Comparative Clinical Trial of Mefloquine and Chloroquine in Symptomatic Falciparum Malaria. Bull World Health Organ. 1983;61(4):713-8. PubMed PMID: 6354507.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. AU - Kofi Ekue,J M, AU - Ulrich,A M, AU - Rwabwogo-Atenyi,J, AU - Sheth,U K, PY - 1983/1/1/pubmed PY - 1983/1/1/medline PY - 1983/1/1/entrez SP - 713 EP - 8 JF - Bulletin of the World Health Organization JO - Bull World Health Organ VL - 61 IS - 4 N2 - A total of 99 male Zambian patients with symptomatic falciparum malaria were treated in a double-blind randomized manner with either mefloquine (1000 mg given in one day) or chloroquine (1500 mg given over 3 days). An S-type response was seen in all the chloroquine patients and 98% of the mefloquine group; one patient in the latter group (2%) showed an RI-type response, but the parasites obtained during the recrudescence were sensitive to both chloroquine and mefloquine in the in vitro microtest, and the patient responded satisfactorily to oral chloroquine. The rate of clearance of parasitaemia was marginally faster in the chloroquine-treated group. The rate of clearance of fever was similar in the two groups. Both drugs were well tolerated and side-effects such as nausea, vomiting, dizziness, loose stools, and pruritus were mild and transient. Pruritus was more common after chloroquine administration and dizziness more common in the mefloquine group. There were no drug-induced alterations in the haematological and biochemical profiles. SN - 0042-9686 UR - https://www.unboundmedicine.com/medline/citation/6354507/A_double_blind_comparative_clinical_trial_of_mefloquine_and_chloroquine_in_symptomatic_falciparum_malaria_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/6354507/ DB - PRIME DP - Unbound Medicine ER -